SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves sharp selloff is drawing attention amid renewed concerns about its heavy debt burden, high borrowing costs and HSBCs bearish assessment of its ability to fund growth. Traders are split between viewing the decline as an overdone move that could fuel a rebound and warning that financing risks could keep pressure on the AI infrastructure provider.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as crude swings on fears of Middle East supply disruptions, including reported attacks on shipping and energy infrastructure and heightened Iran-US tensions. Traders are divided between bulls focused on geopolitical supply risks and bears who see peace-deal headlines, disputed reports, or a normalization of flows unwinding the oil premium.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SLS is drawing attention as traders await the 80-event trigger for the Phase 3 REGAL trial of GPS; the last disclosed count was 78, and claims that the threshold has since been reached remain unconfirmed. Bulls interpret the extended trial as encouraging and speculate about a buyout or ASH update, while skeptics stress that the outcome is still uncertain and the timing unclear.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is drawing attention amid a sharp selloff in AI neocloud stocks, as investors weigh financing risks and warnings that some providers may not survive; traders are frustrated that IREN has lagged peers and debate whether the weakness is justified. Some point to the co-CEOs comments that data-center assets carry no debt and customer prepayments help fund GPU costs, while others remain concerned about sector-wide risk and continued selling.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoins rebound toward the $83,000 area has fueled talk of a breakout and possible short squeeze, with bullish traders pointing to resilient buying. Others call the move a temporary bounce and stress that Bitcoin needs to hold key levels above $82,000$83,000 to sustain momentum.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs slide to fresh lows, amid concerns about Trumps standing ahead of the midterms and Truth Socials declining appeal, dominates discussion. The community is broadly bearish, citing weak business fundamentals and continued selling, while a few traders see scope for a short-term bounce.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Unconfirmed reports of a possible U.S.Iran deal are driving a sharp, volatile SPY rebound, with traders linking the reports and falling oil prices to the move. The community is split between chasing calls and viewing the rally as a fake-news pump that could fade, citing the lack of official confirmation and conflicting denials.

Norwegian Cruise Line Holdings Ltd. engages in the provision of cruise travel services. It offers cruise experiences for travelers with itineraries in Europe, Asia, Australia, New Zealand, South America, Africa, Canada, Bermuda, Caribbean, Alaska and Hawaii. Its brands include Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. The company was founded in 1966 and is headquartered in Miami, FL.

Norwegian Cruise Line Holdings Ltd

Norwegians reported Q3 outlook increase and reaffirmation of its 2026 outlook, alongside Carnivals strong results lifting cruise shares, are driving renewed interest. Bulls point to resilient bookings and heavy short interest as reasons for optimism, while others remain cautious about fuel costs, debt, and NCLHs lagging performance versus peers; squeeze talk is speculative.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhoods steep selloff and continued weakness dominate discussion, with traders pointing to analyst caution and a risk-off market ahead of earnings. Bears see more downside, while bulls argue the pullback is a buying opportunity and watch for support to hold.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Unconfirmed reports of a potential US-Iran deal and a pullback in oil prices are central to the sharp QQQ swings, with traders attributing the rebound to reduced geopolitical risk. The community is divided between buying the move ahead of major tech earnings and warning that the deal chatter may be unreliable and the rally a bull trap, amid continued concern about AI and semiconductor weakness.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension

Gossamer Bio, Inc. (Nasdaq: GOSS) (the Company or Gossamer), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease...

Gossamer Bio Appoints Greg Ciongoli to Board of Directors

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced...

Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split

Gossamer Bio, Inc. (Nasdaq: GOSS) (the Company or Gossamer), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, today...

Gossamer Bio Announces 1-for-80 Reverse Stock Split

Gossamer Bio to Present at Cantor Global Healthcare Conference

Gossamer’s Billion-Dollar Drug Bet Funded with $150M War Chest to Target FDA Approval

Gossamer Bio (NASDAQ:GOSS) is putting serious money behind a high-stakes regulatory bet. The company announced a structured private placement that could deliver up to $250 million, including $150 million of committed capital, as Gossamer races toward a planned September 2026 FDA submission for seralutinib in pulmonary arterial hypertension (PAH). The structure is milestone-driven: roughly $25 million is expected at the initial closing, another $125 million becomes available if the FDA accepts the NDA in 2026, and warrants could provide up to another $100 million if seralutinib ultimately receives FDA approval.

Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval

Gossamer Bio (GOSS) Reports Q2 Loss, Tops Revenue Estimates

Gossamer Bio (GOSS) delivered earnings and revenue surprises of -100.00% and +171.71%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update

Pelthos Therapeutics Inc. (PTHS) Reports Q2 Loss, Lags Revenue Estimates

Pelthos Therapeutics Inc. (PTHS) delivered earnings and revenue surprises of -119.21% and -2.88%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi on October 26, 2015 and is headquartered in San Diego, CA.

Gossamer Bio Inc

Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash?

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>Participants treated with seralutinib recorded a median improvement of 28.2 meters in walking distance, compared with 13.5 meters with placebo.</li><li>The estimated treatment benefit was 13.3 meters, with a p-value of 0.032, falling short of the predefined significance cutoff of 0.025.</li><li>In a predefined subgroup of intermediate- and high-risk individuals, seralutinib delivered a more pronounced benefit.</li></ul>Gossamer Bio Inc. (GOSS) on Monday released topline findings from its late-stage PROSERA trial evaluating seralutinib in patients with pulmonary arterial hypertension (PAH), offering a mixed picture as the company weighs its regulatory strategy.The Phase 3 study assessed the experimental therapy over 24 weeks, measuring improvement in six-minute walk distance compared with placebo.&nbsp;<h2 class="st-heading-2">Primary Endpoint Falls Short</h2>The drug did not achieve the predefined statistical bar for its main goal. Participants treated with seralutinib recorded a median improvement of 28.2 meters in walking distance, compared with 13.5 meters among placebo recipients.&nbsp;The estimated treatment benefit was 13.3 meters, with a p-value of 0.032, falling short of the predefined significance cutoff of 0.025. As a result, the secondary endpoints cannot be formally considered statistically significant, though all four key secondary measures favored seralutinib.Following the announcement,&nbsp;<a href="https://stocktwits.com/symbol/GOSS">Gossamer Bio's stock</a> traded over 82% lower on Monday mid-morning. On Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory while message volume shifted to ‘extremely high’ from high’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_02_23_105719_png_f367574236.webp" alt="GOSS’s Sentiment Meter and Message Volume as of 10:40 a.m. ET on Feb. 23, 2026 | Source: Stocktwits" width="931" height="100"><figcaption>GOSS’s Sentiment Meter and Message Volume as of 10:40 a.m. ET on Feb. 23, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Stronger Results In Higher-Risk Patients</h2>In a predefined subgroup of intermediate- and high-risk individuals, seralutinib delivered a more pronounced benefit. That cohort achieved a 20-meter placebo-adjusted increase in walking distance, along with favorable results across most secondary markers.Patients with connective tissue disease–associated PAH also demonstrated a notable response, with a placebo-adjusted increase of 37 meters in walking distance at 24 weeks.&nbsp;The company plans to meet with the U.S. Food and Drug Administration to determine a regulatory path forward. Gossamer has paused enrollment in SERANATA study to assess the implications of PROSERA’s outcome.GOSS stock has declined by over 70% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-allurion-stock-surge-today/cZRtuSER4yS">Why Did Allurion Stock Surge Over 50% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A view from lab as Ankara University Faculty of Pharmacy, Department of Basic Pharmaceutical Sciences.

Gossamer Bio’s seralutinib did not achieve the predefined statistical bar for its main goal in the phase 3 PROSERA trial. 

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

SpaceX ($SPCX) reports earnings after the close today. What do you expect?

Stocktwits

SpaceX

) reports earnings after the close today. What do you expect?

Current Price	$9.39
Prev Close	$8.43
Open	$8.31
Dividend Yield	0.00%
50-Day Moving Average	$11.81
Beta	2.12
Avg. Volume	277,664.52
PE Ratio	-0.15

52-Week High	$309.60
52-Week Low	$8.31
Market Capitalization	$51.51M
EPS (Annual)	-$59.64
Price to Book	-0.55
Revenue Per Employee	$299,203.70

Feed

News

Sentiment

Earnings

Fundamentals

Info

GOSS Fundamentals